Source:http://linkedlifedata.com/resource/pubmed/id/10823767
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2000-7-20
|
| pubmed:abstractText |
The protective efficacy of an oral inactivated whole cell Vibrio cholerae plus recombinant B subunit cholera vaccine was determined against El Tor cholera among Peruvian children and adults (2-65 years old) in a randomized, double-blind manner. Study subjects received 2 doses of vaccine or placebo 2 weeks apart, followed by a booster dose 10 months later. Surveillance for cholera was performed actively, with 2 visits per week to each household, and passively, at a local hospital. Stool samples were collected during diarrhea episodes and were cultured for V. cholerae. A total of 17,799 persons received 2 doses of vaccine or placebo, and 14,997 of these persons received the booster dose. After 2 doses (first surveillance period), V. cholerae biotype O1 was isolated from 17 vaccinees and 16 placebo recipients, demonstrating vaccine efficacy (VE) of -4%. After 3 doses (second surveillance period), V. cholerae O1 was isolated from 13 vaccinees and 32 placebo recipients, demonstrating VE of 61% (95% confidence interval ¿CI, 28%-79%). In the second surveillance period, the VE for illness requiring hospitalization was 82% (95% CI, 27%-96%). VE was also higher for persons >15 years old (VE, 72%; 95% CI, 28%-89%).
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0022-1899
|
| pubmed:author |
pubmed-author:BéguéR ERE,
pubmed-author:BautistaCC,
pubmed-author:CárdenasVV,
pubmed-author:EcheverriaPP,
pubmed-author:GaillourAA,
pubmed-author:GilmanRR,
pubmed-author:MezaRR,
pubmed-author:PerezJJ,
pubmed-author:PugaRR,
pubmed-author:SadoffJJ,
pubmed-author:SanchezJ LJL,
pubmed-author:TaylorD NDN
|
| pubmed:issnType |
Print
|
| pubmed:volume |
181
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1667-73
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10823767-Administration, Oral,
pubmed-meshheading:10823767-Adolescent,
pubmed-meshheading:10823767-Adult,
pubmed-meshheading:10823767-Aged,
pubmed-meshheading:10823767-Child,
pubmed-meshheading:10823767-Child, Preschool,
pubmed-meshheading:10823767-Cholera,
pubmed-meshheading:10823767-Cholera Toxin,
pubmed-meshheading:10823767-Cholera Vaccines,
pubmed-meshheading:10823767-Diarrhea,
pubmed-meshheading:10823767-Feces,
pubmed-meshheading:10823767-Humans,
pubmed-meshheading:10823767-Middle Aged,
pubmed-meshheading:10823767-Peru,
pubmed-meshheading:10823767-Population Surveillance,
pubmed-meshheading:10823767-Vaccines, Synthetic,
pubmed-meshheading:10823767-Vibrio cholerae,
pubmed-meshheading:10823767-Virus Shedding
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru.
|
| pubmed:affiliation |
Dept. of Enteric Infections, Division of Communicable Diseases and Immunology, Walter Reed Army Institute of Research, Washington, DC 20307-5100, USA. David.Taylor@na.amedd.army.mil.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, Non-P.H.S.,
Randomized Controlled Trial
|